Elyxium Wealth’s Charles River Laboratories CRL Stock Holding History

Elyxium Wealth’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-233	Closed	-$46.5K	–	400
2025 Q4	$46.5K	Buy	+233	New	+$42.3K	0.01%	372

Other funds holding CRL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Elyxium Wealth's CRL Position: Q1 2026 in Review

Elyxium Wealth sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 233 shares — an estimated $46.5K sold.

Elyxium Wealth first reported a position in CRL in Q4 2025 and held it in 1 quarter. The position peaked at $46.5K in Q4 2025. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Elyxium Wealth reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
Elyxium Wealth sold 233 Charles River Laboratories shares in Q1 2026, an estimated $46.5K.
Elyxium Wealth first reported a position in Charles River Laboratories in Q4 2025 and held it in 1 quarter.
Elyxium Wealth's Charles River Laboratories position peaked at $46.5K in Q4 2025.
558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Elyxium Wealth's 13F filing for Q1 2026, filed 6 May 2026.